148 related articles for article (PubMed ID: 38743100)
1. [Prostate cancer screening-current overview].
De Vrieze M; Hübner A; Al-Monajjed R; Albers P; Radtke JP; Schimmöller L; Boschheidgen M
Radiologie (Heidelb); 2024 Jun; 64(6):479-487. PubMed ID: 38743100
[TBL] [Abstract][Full Text] [Related]
2. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
3. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.
Krilaviciute A; Becker N; Lakes J; Radtke JP; Kuczyk M; Peters I; Harke NN; Debus J; Koerber SA; Herkommer K; Gschwend JE; Meissner VH; Benner A; Seibold P; Kristiansen G; Hadaschik B; Arsov C; Schimmöller L; Giesel FL; Antoch G; Makowski M; Wacker F; Schlemmer HP; Kaaks R; Albers P
Eur Urol Oncol; 2023 Dec; 6(6):566-573. PubMed ID: 37806841
[TBL] [Abstract][Full Text] [Related]
4. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
6. Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial.
Krilaviciute A; Albers P; Lakes J; Radtke JP; Herkommer K; Gschwend J; Peters I; Kuczyk M; Koerber SA; Debus J; Kristiansen G; Schimmöller L; Antoch G; Makowski M; Wacker F; Schlemmer H; Benner A; Giesel F; Siener R; Arsov C; Hadaschik B; Becker N; Kaaks R
Int J Cancer; 2023 Mar; 152(5):854-864. PubMed ID: 36121664
[TBL] [Abstract][Full Text] [Related]
7. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
8. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
[TBL] [Abstract][Full Text] [Related]
10. [PSA screening and molecular markers].
Lakes J; Arsov C
Urologe A; 2019 May; 58(5):486-493. PubMed ID: 30874831
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.
Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
Eur Urol Oncol; 2021 Oct; 4(5):731-739. PubMed ID: 34364829
[TBL] [Abstract][Full Text] [Related]
13. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial.
Arsov C; Albers P; Herkommer K; Gschwend J; Imkamp F; Peters I; Kuczyk M; Hadaschik B; Kristiansen G; Schimmöller L; Antoch G; Rummeny E; Wacker F; Schlemmer H; Benner A; Siener R; Kaaks R; Becker N
Int J Cancer; 2022 Jun; 150(11):1861-1869. PubMed ID: 35076933
[TBL] [Abstract][Full Text] [Related]
15. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
[TBL] [Abstract][Full Text] [Related]
17. [Prostate cancer - diagnostics and screening].
Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38647107
[TBL] [Abstract][Full Text] [Related]
18. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
Rais-Bahrami S; Siddiqui MM; Vourganti S; Turkbey B; Rastinehad AR; Stamatakis L; Truong H; Walton-Diaz A; Hoang AN; Nix JW; Merino MJ; Wood BJ; Simon RM; Choyke PL; Pinto PA
BJU Int; 2015 Mar; 115(3):381-8. PubMed ID: 24447678
[TBL] [Abstract][Full Text] [Related]
20. [Risk-adapted prostate cancer screening-update 2021].
Al-Monajjed R; Arsov C; Albers P
Urologe A; 2021 May; 60(5):592-601. PubMed ID: 33792743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]